Clinical Trial Update: Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating how AML molecular subtype and early measurable residual disease can guide initial treatment choices.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Ruijin Hospital | Conditions: Acute Myeloid Leukemia (AML) | Phase 2 | Status: NOT_YET_RECRUITING